TOP2B and neuroblastoma: We used large-scale preclinical drug screening data to identify CX-5461 as exhibiting a selective and reproducible cytotoxic effect in high-risk neuroblastoma and we discovered that the primary target of CX-5461 at pharmacologically relevant concentrations is TOP2B.